pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›OLINVYK
drug
save

OLINVYK

Marketedupdated 3mo ago
by Trevena Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval16 co-mentions · 4 sources

all catalysts(4)

approval · 4
Aug 7, 2020
approval
6y ago
OLINVYK (OLICERIDINE) — FDA approval
OLINVYK
→
Mar 4, 2021
approval
5y ago
OLINVYK (OLICERIDINE) — FDA approval
OLINVYK
→
Dec 15, 2023
approval
3y ago
OLINVYK (OLICERIDINE) — FDA approval
OLINVYK
→
Dec 22, 2025
approval
8mo ago
OLINVYK (OLICERIDINE) — FDA approval
OLINVYK
→

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 23, 2032
~5.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

  • Mar 23, 2032compositionUS 11077098
  • Mar 23, 2032compositionUS 11077098
  • Mar 23, 2032compositionUS 11077098
  • Mar 23, 2032compositionUS 11931350
  • Mar 23, 2032compositionUS 11931350
  • Mar 23, 2032compositionUS 11931350
  • Mar 23, 2032compositionUS 8835488
  • Mar 23, 2032compositionUS 8835488
  • Mar 23, 2032compositionUS 8835488
  • Mar 23, 2032compositionUS 9309234
  • Mar 23, 2032compositionUS 9309234
  • Mar 23, 2032compositionUS 9309234
  • Mar 23, 2032formulationUS 9642842
  • Mar 23, 2032formulationUS 9642842
  • Mar 23, 2032formulationUS 9642842

News(0)

no news has mentioned this drug yet

brand
OLINVYK
generic
OLICERIDINE
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?